Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Udine – page 9

251 clinical trials in Udine, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Udine at a glance
251
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

251 trials in Udine

Open in trial search

Non-small cell lung cancer stage IV

Not yet recruiting

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Not yet recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Psoriatic arthropathy

Not yet recruiting

Add‑on Unsaturated Fatty Acids with TNF‑Alpha Inhibitor Drug Combination in Patients with Psoriatic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon

Graft versus host disease

Not yet recruiting

A study to evaluate the effectiveness of MC0518 (mesenchymal stromal cells) in adults with acute graft-versus-host disease that has not responded to steroids and ruxolitinib

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mesenchymal Stromal Cells, Ex Vivo Cultured
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Plasma cell myeloma refractory

Not yet recruiting

Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Testing Personalized Antibiotic Treatment with Amoxicillin and Clavulanic Acid for Children with Febrile Urinary Tract Infections

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo

Psoriatic arthropathy

Not yet recruiting

A Study of Guselkumab and Ciclosporin in Patients with Early Psoriatic Arthritis Transitioning from Skin to Joint Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Azienda Sanitaria Universitaria Friuli Centrale

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Udine

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials investigating treatments for various cancer types, including leukemia, gastric cancer, and multiple myeloma. Studies focus on targeted therapies and immunotherapy approaches.

  • Chronic Myeloid Leukemia Treatment
  • Gastroesophageal Cancer Therapy
  • Advanced Pancreatic Cancer Management

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Autoimmune Conditions

Studies examining new therapeutic options for inflammatory and autoimmune disorders, with particular focus on psoriatic arthritis and Sjögren's Syndrome.

  • Biomarker Analysis in Psoriatic Arthritis
  • Novel Treatments for Inflammatory Conditions
  • Long-term Disease Management

Trials aim to evaluate both safety and efficacy of innovative biological treatments.

03 Cardiovascular Studies

Research focusing on heart health and prevention, including studies of heart failure prevention and treatment of recurrent pericarditis.

  • Heart Failure Prevention Strategies
  • Pericarditis Treatment Innovation
  • Cardiovascular Risk Management

Investigations center on both preventive approaches and therapeutic interventions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.